查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1934750

消毒劑和清潔劑：市場佔有率分析、行業趨勢和統計數據、成長預測（2026-2031 年）

Antiseptics And Disinfectants - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)
出版日期: | 出版商: Mordor Intelligence | 英文 130 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2025年消毒劑和清潔劑市值為408.8億美元，預計2031年將達到649.7億美元，高於2026年的441.7億美元。

預計在預測期（2026-2031 年）內，複合年成長率將達到 8.05%。

消毒劑和殺菌劑市場-IMG1

目前的支出模式顯示，感染控制預算與醫院因醫療相關感染（HAI）而遭受的經濟處罰之間有明顯的關聯。預防性技術的資金投入成長速度超過了治療性藥物，反映出醫院採購部門在策略上優先考慮預防而非治療。大量高頻接觸表面和需要每天多次消毒的可重複使用醫療設備的普及，進一步擴大了這個市場機會。穩定的市場擴張表明，由於感染控制是醫療機構的強制性支出項目，因此需求在很大程度上不受經濟放緩的影響。因此，即使消費者市場的需求不斷成長，製造商仍在優先考慮醫院級產品的產能。

監管審查的加強非但沒有抑制需求，反而加速了需求成長，因為醫療服務提供者更傾向於選擇符合法規、未來處罰風險較低的下一代化學品。美國環保署 (EPA) 於 2024 年 3 月最終確定的環氧乙烷滅菌器排放90% 的要求就是一個典型的例子，這促使買家轉向低殘留酶基混合物和氣化過氧化氫系統。圍繞這些替代技術構建的智慧財產權組合在併購中獲得了積極評價，反映出企業正在策略性地轉向更安全、更環保的選擇。投資者還指出，醫院基礎設施的使用壽命較長，確保了相容配方的持續供應，這意味著如果經濟逆風有限，實際成長可能超過已公佈的 8% 複合年成長率。

全球消毒劑和清潔劑市場趨勢及洞察

本院獲得性感染呈上升趨勢

醫院感染（HAI）持續上升，歐洲醫療機構每年報告的病例高達890萬例，給公立和私立醫院的預算都帶來了壓力。由於每例感染都會對醫院造成收入損失，因此預防工作被列為優先事項，這也推動了消毒劑和清潔劑市場的成長。擁有先進監測系統的醫療機構往往更早採用高效消毒劑，因為數據透明化使經營團隊能夠清楚地了解預防投資的回報率。

手術數量增加

手術量持續成長，尤其是在門診手術中心（ASC），其感染率僅為0.1%（相較之下，醫院的感染率為1%）。這項成功促使醫療機構更加依賴專業的消毒通訊協定，以實現手術室的快速週轉。供應商若能針對門診手術中心的需求客製化消毒劑包裝規格和作用時間，便可在不與現有醫院產品線直接競爭的情況下，贏得消毒劑和清潔劑市場佔有率。

嚴格的監管要求

美國環保署 (EPA) 已強制要求將環氧乙烷滅菌設備的排放減少 90%，這將影響美國約一半的醫療設備滅菌流程。合規成本正促使醫院考慮低溫替代方法。新興研究表明，採用這些替代方法的機構更有可能統一使用同一供應商提供的兼容表面消毒劑，從而加劇對供應商的依賴。

細分市場分析

根據市場規模估算，到2025年，季銨化合物（QACs）將佔消毒劑和清潔劑市場的27.45%，而酵素製劑預計將在2031年之前以8.75%的複合年成長率（CAGR）實現最快成長。儘管醫院重視QACs的殘留效力，但日益嚴格的監管審查正推動採購轉向酵素製劑，因為酵素製劑能夠分解生物膜且不留有毒殘留物。 QAC和酵素製劑的組合配方有望成為兼顧功效和環保目標的過渡性產品線。

由於成本低廉且起效迅速，氯化合物和醇醛混合物仍被廣泛應用於高頻擦拭巾消毒。而雙胍類藥物（如氯己定）因其持久的消毒效果，仍是術前皮膚消毒的首選。這意味著，即使整體市場趨勢轉向更環保的解決方案，與臨床通訊協定相關的特定化學物質仍將保持其重要性。

到2025年，液體消毒劑將佔消毒劑和清潔劑市場規模的51.10%，而擦拭巾預計年複合成長率將達到9.05%，因為醫院需要劑量可控的一次性產品。此外，擦拭巾有助於庫存管理，簡化預算，因為其單位銷售與患者數量密切相關。

雖然噴霧劑在大面積緊急消毒方面仍然很受歡迎，但凝膠和泡沫劑在慢性傷口診所越來越受歡迎，因為它們兼具消毒和癒合功能。其原理是，泡棉包裝可以精確地應用於垂直和不規則表面，從而減少浪費並提升顧客的價值感知。

區域分析

預計到2025年，北美將繼續保持其在消毒劑和清潔劑市場的領先地位，佔據37.60%的市場佔有率。這主要得益於醫療相關感染（HAI）的高額罰款以及美國環保署（EPA）針對環氧乙烷排放的新規。 EPA和FDA之間的監管協調縮短了技術升級的決策週期，並加快了產品更新換代的速度。在加州等感染率最高的州，醫院往往反應更快，因為公共報告要求給經營團隊帶來了壓力。

亞太地區以9.12%的複合年成長率呈現最快成長勢頭，主要得益於大規模的醫院建設和對洗手衛生的重視。儘管本地產量不斷提高，但高階進口產品在加護病房仍然佔據主導地位，這表明在品質認知方面存在差距。當國際品牌進入區域性城市時，它們可能會在本地競爭對手提升配方標準之前搶佔市場佔有率。

歐洲正經歷穩定成長，主要得益於嚴格的環境毒性標準以及老年人口不斷成長、感染疾病風險更高的現狀。採購政策優先考慮揮發性有機化合物（VOC）含量低的產品，並鼓勵製造商對傳統產品進行配方改良。歐盟的環境法規往往成為事實上的全球標準，這使得率先採用這些法規的企業在出口到其他受監管市場時更具優勢。

其他福利：

  • Excel格式的市場預測（ME）表
  • 3個月的分析師支持

目錄

第1章 引言

  • 研究假設和市場定義
  • 調查範圍

第2章調查方法

第3章執行摘要

第4章 市場情勢

  • 市場概覽
  • 市場促進因素
    • 本院獲得性感染呈上升趨勢
    • 手術數量增加
    • 提高衛生管理和感染控制意識
    • 透過加強內視鏡再處理強制性標準，促進高水準消毒劑的引入。
    • 醫療領域的成長和住院人數的增加
    • 創新的生產方法與技術
  • 市場限制
    • 嚴格的監管要求
    • 先進醫療設備的滅菌消毒劑面臨的挑戰
    • 揮發性季銨化合物原料成本
    • 過渡到使用一次性設備/減少可重複使用設備的消毒次數
  • 供應鏈分析
  • 監管和技術趨勢
  • 波特五力分析
    • 新進入者的威脅
    • 買方的議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭對手之間的競爭

第5章 市場規模與成長預測

  • 依產品類型
    • 季銨化合物
    • 氯化合物
    • 醇和醛類化合物
    • 雙胍類和碘衍生物
    • 酵素
    • 酚類和其他
  • 配方
    • 液體
    • 噴霧劑和氣霧劑
    • 消毒紙巾
    • 凝膠泡沫
  • 透過使用
    • 表面消毒劑
    • 醫療設備消毒劑
    • 酵素性清潔劑
    • 皮膚和傷口消毒劑
  • 最終用戶
    • 醫院和診所
    • 門診/日間手術中心
    • 其他
  • 按地區
    • 北美洲
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 義大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 韓國
      • 澳洲
      • 亞太其他地區
    • 中東
      • GCC
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章 競爭情勢

  • 市場集中度
  • 市佔率分析
  • 公司簡介
    • Solventum Corporation
    • STERIS plc
    • Ecolab Inc.
    • Reckitt Benckiser Group plc
    • The Clorox Company
    • Procter & Gamble Co.
    • SC Johnson Professional
    • Johnson & Johnson
    • Cardinal Health Inc.
    • Schulke & Mayr GmbH
    • Metrex Research, LLC
    • GSK plc
    • Molnlycke Health Care AB
    • Pal International Ltd.
    • Diversey Holdings, Ltd.
    • GOJO Industries, Inc.
    • Zep Inc.
    • Kimberly-Clark Corporation

第7章 市場機會與未來展望

簡介目錄
Product Code: 69948

The Antiseptics and Disinfectants market was valued at USD 40.88 billion in 2025 and estimated to grow from USD 44.17 billion in 2026 to reach USD 64.97 billion by 2031, at a CAGR of 8.05% during the forecast period (2026-2031).

Antiseptics And Disinfectants - Market - IMG1

Current spending patterns reveal a clear correlation between infection-control budgets and the financial penalties hospitals incur for healthcare-associated infections (HAIs). Capital allocations for preventive technologies are rising faster than for therapeutic drugs, reflecting a strategic preference for prevention over cure in hospital purchasing departments. The scale of the opportunity is reinforced by the large installed base of high-touch surfaces and reusable medical devices that require disinfection multiple times daily. Consistent market expansion suggests that demand is broadly resilient to economic slowdowns, as infection control is a non-discretionary purchase for healthcare providers. Manufacturers are therefore prioritizing production capacity for hospital-grade products, even as demand from consumer segments grows.

Regulatory scrutiny is accelerating rather than dampening demand, because providers prefer compliant, next-generation chemistries that are less likely to trigger future penalties. The United States Environmental Protection Agency's 90 % emission reduction mandate for ethylene oxide sterilizers, finalised in March 2024 is a prime example: it has pushed purchasers toward low-residue enzymatic blends and vaporised hydrogen peroxide systems . Intellectual property portfolios built around these alternatives are commanding premium valuations in mergers and acquisitions, reflecting a strategic shift toward safer, greener options. Investors also note the long useful life of hospital infrastructure, which locks in repeat sales of compatible formulations, suggesting that actual growth may exceed the headline 8 % CAGR if economic headwinds remain modest.

Global Antiseptics And Disinfectants Market Trends and Insights

Growing Incidences of Hospital Acquired Infections

HAIs continue to climb, with European facilities reporting 8.9 million annual cases, placing budgetary strain on public and private hospitals alike . Hospitals face lost revenue per infection episode, so prevention budgets are receiving priority, which in turn sustains growth in the Antiseptics and Disinfectants market. Facilities with advanced surveillance programs tend to adopt high-performance disinfectants early because data transparency makes the ROI on prevention visible to management.

Increasing Number of Surgical Procedures

Surgical volumes are rising, particularly in ambulatory surgery centers (ASCs) where infection rates sit at just 0.1 % compared with 1 % in hospitals. This success raises institutional confidence in specialized disinfectant protocols designed for rapid room turnover. Suppliers that tailor packaging sizes and contact times for ambulatory surgery centers can gain Antiseptics and Disinfectants market share without direct head-to-head competition with incumbent hospital product lines.

Stringent Regulatory Requirements

The Environmental Protection Agency (EPA) has mandated 90% emission cuts for ethylene oxide sterilizers, affecting roughly half of all device sterilization in the United States. Compliance costs encourage hospitals to trial on-site low-temperature alternatives. A fresh inference is that facilities adopting such alternatives will standardize on compatible surface disinfectants from the same suppliers, reinforcing vendor stickiness.

Other drivers and restraints analyzed in the detailed report include:

  1. Rising Awareness of Hygiene and Infection Control
  2. Growth in Healthcare Sector and Hospital Admissions
  3. Issues Related to Sterilization and Disinfectants of Advanced Medical Instruments

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Market size estimates show Quaternary Ammonium Compounds (QACs) hold 27.45 % Antiseptics and Disinfectants market share in 2025, while enzymes record the fastest CAGR of 8.75 % through 2031. Hospitals value QACs for residual activity, but growing regulatory attention is nudging procurement teams toward enzymatic blends that degrade biofilms without leaving toxic residues. A clear inference is that formulators combining QACs with enzymes could offer a transitional product line that meets both efficacy and environmental goals.

Chlorine compounds and alcohol-aldehyde mixes continue serving high-frequency wipe-down tasks thanks to low cost and rapid action. Biguanides such as chlorhexidine remain favored for pre-operative skin prep owing to extended bactericidal persistence. The inference here is that niche chemicals sustain relevance when tied to clinical protocols, even if overall market momentum shifts toward greener solutions.

Liquids account for 51.10 % of Antiseptics and Disinfectants market size in 2025, but wipes display a 9.05% forecast CAGR as hospitals seek dose-controlled, single-use formats. The fresh inference is that wipes also aid inventory control because unit counts align closely with patient volumes, simplifying budgeting.

Sprays remain popular for emergency decontamination of wide areas, while gels and foams gain favor in chronic-wound clinics for their combined disinfectant and healing attributes. An inference is that foam packaging allows precise application on vertical or irregular surfaces, reducing wastage and boosting perceived value.

The Antiseptics and Disinfectants Market Report is Segmented by Product Type (Quaternary Ammonium Compounds, Chlorine Compounds, and More), Formulation (Liquid, Wipes, and More), Application (Enzymatic Cleaners, Medical Device Disinfectants, More), End User (Hospitals & Clinics, Ambulatory & Day-Surgery Centers, and Others), and Geography (North America and More). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America leads with 37.60% Antiseptics and Disinfectants market share in 2025, fueled by high HAI penalties and new EPA rules curbing ethylene oxide emissions. Regulatory alignment between the EPA and FDA is compressing decision cycles for technology upgrades, accelerating product replacement rates. Hospitals in states with the highest infection counts, such as California, are often the first to move because public reporting pressures executive teams.

The Asia-Pacific region shows the fastest growth rate of 9.12% CAGR, driven by large-scale hospital construction and a cultural emphasis on hand hygiene. Local production is increasing, yet premium imports still dominate critical care units, indicating gaps in quality perception. Global brands entering tier-2 cities may gain share before local competitors improve formulation standards.

Europe maintains steady growth underpinned by stringent eco-toxicity standards and a large aging population susceptible to infections. Procurement policies favor products with reduced volatile organic compounds, incentivizing manufacturers to reformulate legacy lines. EU environmental rules often serve as de facto global benchmarks, and early compliance can provide export advantages in other regulated markets.

  1. Solventum Corporation
  2. STERIS
  3. Ecolab
  4. Reckitt Benckiser Group
  5. The Clorox Company
  6. Procter & Gamble
  7. SC Johnson Professional
  8. Johnson & Johnson
  9. Cardinal Health
  10. Schulke & Mayr GmbH
  11. Metrex Research, LLC
  12. GlaxoSmithKline
  13. Molnlycke Health Care
  14. Pal International Ltd.
  15. Diversey Holdings, Ltd.
  16. GOJO Industries, Inc.
  17. Zep Inc.
  18. Kimberly-Clark Worldwide

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Incidences Of Hospital Acquired Infections
    • 4.2.2 Increasing Number Of Surgical Procedures
    • 4.2.3 Rising Awareness Of Hygeiene And Infection Control
    • 4.2.4 Mandatory Endoscope Reprocessing Standards Strengthening High-Level Disinfectant Uptake
    • 4.2.5 Growth In The Healthcare Sector And Hospital Admissions
    • 4.2.6 Innovative Production Formulations And Technologies
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Requirements
    • 4.3.2 Issues Related To The Sterilization And Disinfectants Of Advanced Medical Instruments
    • 4.3.3 Volatile Quaternary Ammonium Compound Feedstock Costs
    • 4.3.4 Shift To Single-Use Instruments Shrinking Reusable Disinfection Volumes
  • 4.4 Supply-Chain Analysis
  • 4.5 Regulatory & Technological Outlook
  • 4.6 Porter's Five Forces Analysis
    • 4.6.1 Threat of New Entrants
    • 4.6.2 Bargaining Power of Buyers
    • 4.6.3 Bargaining Power of Suppliers
    • 4.6.4 Threat of Substitutes
    • 4.6.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Product Type
    • 5.1.1 Quaternary Ammonium Compounds
    • 5.1.2 Chlorine Compounds
    • 5.1.3 Alcohols & Aldehydes
    • 5.1.4 Biguanides & Iodine Derivatives
    • 5.1.5 Enzymes
    • 5.1.6 Phenolic & Others
  • 5.2 By Formulation
    • 5.2.1 Liquids
    • 5.2.2 Sprays & Aerosols
    • 5.2.3 Wipes
    • 5.2.4 Gels & Foams
  • 5.3 By Application
    • 5.3.1 Surface Disinfectants
    • 5.3.2 Medical Device Disinfectants
    • 5.3.3 Enzymatic Cleaners
    • 5.3.4 Skin & Wound Antiseptics
  • 5.4 By End User
    • 5.4.1 Hospitals & Clinics
    • 5.4.2 Ambulatory & Day-Surgery Centers
    • 5.4.3 Others
  • 5.5 By Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 South Korea
      • 5.5.3.5 Australia
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global-level Overview, Market-level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
    • 6.3.1 Solventum Corporation
    • 6.3.2 STERIS plc
    • 6.3.3 Ecolab Inc.
    • 6.3.4 Reckitt Benckiser Group plc
    • 6.3.5 The Clorox Company
    • 6.3.6 Procter & Gamble Co.
    • 6.3.7 SC Johnson Professional
    • 6.3.8 Johnson & Johnson
    • 6.3.9 Cardinal Health Inc.
    • 6.3.10 Schulke & Mayr GmbH
    • 6.3.11 Metrex Research, LLC
    • 6.3.12 GSK plc
    • 6.3.13 Molnlycke Health Care AB
    • 6.3.14 Pal International Ltd.
    • 6.3.15 Diversey Holdings, Ltd.
    • 6.3.16 GOJO Industries, Inc.
    • 6.3.17 Zep Inc.
    • 6.3.18 Kimberly-Clark Corporation

7 Market Opportunities & Future Outlook

  • 7.1 White-Space & Unmet-Need Assessment